Citation Impact
Citing Papers
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
2006
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
C-terminal region of activation-induced cytidine deaminase (AID) is required for efficient class switch recombination and gene conversion
2014 StandoutNobel
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Proteasome-dependent Processing of Topoisomerase I-DNA Adducts into DNA Double Strand Breaks at Arrested Replication Forks
2009
Hallmarks of Cancer: The Next Generation
2011 Standout
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
The DNA-damage response in human biology and disease
2009 StandoutNature
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Worldwide Variations in Colorectal Cancer
2009
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
2007
Molecular identification of a renal urate–anion exchanger that regulates blood urate levels
2002 StandoutNature
Repair of cisplatin‐DNA adducts by protein extracts from human ovarian carcinoma
1994
Cisplatin resistance in human cancers
1991
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
1995 Standout
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
2008
Nucleotide signalling during inflammation
2014 StandoutNature
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Targeting hypoxia cell signaling for cancer therapy
2007
Adaptive enhancement and kinetics of nucleotide excision repair in humans
1999
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
2000
Tumor necrosis factor, cancer and anticancer therapy
2004
Regulation of Platinum-Compound Cytotoxicity by the c-Jun N-Terminal Kinase and c-Jun Signaling Pathway in Small-Cell Lung Cancer Cells
2002
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
2001
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
2004
The resurgence of platinum-based cancer chemotherapy
2007 Standout
The antiandrogen withdrawal syndrome
1997
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Purinergic P2Y2 Receptors Promote Neutrophil Infiltration and Hepatocyte Death in Mice With Acute Liver Injury
2012
The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes
1987
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
2004
Oxaliplatin (L-OHP): a new reality in colorectal cancer
1998
Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer
2010
DNA repair deficiency as a therapeutic target in cancer
2008
Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines
2003
Molecular mechanisms of cisplatin resistance
2011 Standout
Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53
2006
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Global cancer statistics
2011 Standout
Cisplatin and DNA repair in cancer chemotherapy
1995
Preclinical Perspectives on Platinum Resistance
2000
Cellular processing of platinum anticancer drugs
2005 Standout
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells
2005
Cisplatin resistance: Preclinical findings and clinical implications
2010
Transplacental cisplatin exposure induces persistent fetal mitochondrial and genomic DNA damage in patas monkeys
1997
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
2007
The microenvironment of the tumour–host interface
2001 StandoutNature
Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin
2002
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
2002
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei
2006
Enhanced repair of a cisplatin‐damaged reporter chloramphenicol‐O‐acetyltransferase gene and altered activities of DNA polymerases α and β, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy
1994
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
2006
Reactivating the expression of methylation silenced genes in human cancer
2002
Cross-resistance to cisplatin in cells with acquired resistance to copper
2004
Platinum Compounds in the Treatment of Advanced Breast Cancer
2001
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
2003
Thalidomide
2004
Hsp70 and CHIP Selectively Mediate Ubiquitination and Degradation of Hypoxia-inducible Factor (HIF)-1α but Not HIF-2α
2009 StandoutNobel
Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line
1996 StandoutNobel
Ongoing and unsaid on oxaliplatin: the hope
1998
Antiangiogenic therapies for high-grade glioma
2009
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts
1995
Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
2007
Cancer-related inflammation
2008 StandoutNature
DNA Repair Excision Nuclease Attacks Undamaged DNA
2001 StandoutNobel
New platinum antitumor complexes
1993
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
1994
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency
2008
Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure
1997
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
2004
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach
1993
Mechanisms of resistance to cisplatin
2001
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
The Management of Gout
1996
Cancer of the Ovary
2004 Standout
Recombinant Toxins for Cancer Treatment
1991 Science
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
1990
Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain
2003
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells.
1991 StandoutNobel
Ovarian Cancer
2008
Mechanisms of DNA Excision Repair
1994 StandoutScienceNobel
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
STEROID HORMONE WITHDRAWAL SYNDROMES
1997
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
2001
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Cellular and molecular pharmacology of oxaliplatin.
2002
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).
1994
Human Testis-Determining Factor SRY Binds to the Major DNA Adduct of Cisplatin and a Putative Target Sequence with Comparable Affinities
1998
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Highly specific and sensitive method for measuring nucleotide excision repair kinetics of ultraviolet photoproducts in human cells
2013 StandoutNobel
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
2005
Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study
2002
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin
1994
Growth Factors and Cancer
1991 StandoutScience
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Activation of the p53 DNA Damage Response Pathway after Inhibition of DNA Methyltransferase by 5-Aza-2′-deoxycytidine
2001
Molecular Determinants of the Cytotoxicity of Platinum Compounds
2004
Protein interactions with platinum–DNA adducts: from structure to function
2004
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
1994 StandoutNobel
Global cancer statistics, 2012
2015 Standout
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
1987
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
APE1 is dispensable for S-region cleavage but required for its repair in class switch recombination
2014 StandoutNobel
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
2003
Repair of DNA–polypeptide crosslinks by human excision nuclease
2006 StandoutNobel
High-dose carboplatin in refractory ovarian cancer patients.
1987
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
1999
Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity
2007
Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA
1996
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
2014 StandoutNobel
Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
2007
Works of Eddie Reed being referenced
Characterization of the DNA damage recognized by the antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA
1990
SU5416 inhibited VEGF and HIF-1α expression through the PI3K/AKT/p70S6K1 signaling pathway
2004
Suramin's Development: What Did we Learn?
2002
Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance
1995
Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells
1997
Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry
1991
Modulation of excision repair cross complementation group 1 (ercc-1) mrna expression by pharmacological agents in human ovarian carcinoma cells
1999
ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven
2004
Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
1993
Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells
1998
Pharmacokinetics and Relative Bioavailability of Carboxyamido-Triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters
1998
Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3
2001
9-β-d-Arabinofuranosyl-2-fluoroadenine Inhibits Expression of Vascular Endothelial Growth Factor through Hypoxia-Inducible Factor-1 in Human Ovarian Cancer Cells
2004
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues
1997
Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines
1992
The measurement of cisplatin-DNA adduct levels in testicular cancer patients
1988
Prevention of cisplatin–DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors
2000
PHARMACOKINETICS OF ELEMENTAL PLATINUM (ULTRAFILTRATE AND TOTAL) AFTER A THIRTY MINUTE INTRAVENOUS INFUSION OF ORMAPLATIN
1997
Pharmacogenetic Associations ofCYP2C19Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide
2002
Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification
1996
Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer
1996
Expression of excision repair genes in non-malignant bone marrow from cancer patients
1993
Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
2003
DNA Adducts of Cisplatin in Nucleated Peripheral Blood Cells and Tissues of Cancer Patients
2015
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
1993
A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer
1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
1998
Alkylating agents and platinum
1991
A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis
1998
Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancer
2004
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
1991
Polyclonal Antibodies to Quantitate Cis-Diamminedichloroplatinum(II)-DNA Adducts in Cancer Patients and Animal Models
1985
cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
1987
Development of a federally funded demonstration colorectal cancer screening program.
2008
Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways
2005
Platinum Drug-DNA Interactions in Human Tissues Measured by Cisplatin-DNA Enzyme-Linked Immunosorbent Assay and Atomic Absorbance Spectroscopy
1993
Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)
2004
Allopurinol kinetics
1978
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
1995
Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer
2003
Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.
2003
Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
2001